We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Guardant Health Inc
23 own
7 watching
Current Price
$28.08
$0.21
(0.75%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,884.05M
52-Week High
62.75
52-Week Low
20.67
Average Volume
2.99M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,884.05M52-Week High62.7552-Week Low20.67Average Volume2.99MDividend Yield--P/E Ratio--What does the Guardant Health Inc do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Read More
How much money does Guardant Health Inc make?
News & Events about Guardant Health Inc.
Business Wire
23days ago
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the...
Business Wire
1month ago
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE...
Business Wire
2 months ago
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield, Guardant Healths blood test to screen for colorectal cancer (CRC...
Globe Newswire
2 months ago
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study resultsSermonix anticipates dosing the first patient in first half of 2023 COLUMBUS...
Zolmax
2 months ago
Guardant Health (NASDAQ:GH Get Rating) had its price target trimmed by Piper Sandler from $50.00 to $35.00 in a report published on Friday, The Fly reports. The firm currently has a neutral rating on the stock. GH has been the subject of several other research reports. BTIG Research cut their price ...
Frequently Asked Questions
Frequently Asked Questions
What is Guardant Health Inc share price today?
Can Indians buy Guardant Health Inc shares?
How can I buy Guardant Health Inc shares from India?
Can Fractional shares of Guardant Health Inc be purchased?
What are the documents required to start investing in Guardant Health Inc stocks?
What is today’s traded volume of Guardant Health Inc?
What is today’s market capitalisation of Guardant Health Inc?
What is the 52-Week High and Low Range of Guardant Health Inc?
What percentage is Guardant Health Inc down from its 52-Week High?
What percentage is Guardant Health Inc up from its 52-Week Low?
Current Price
$28.08
$0.21
(0.75%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.